304 related articles for article (PubMed ID: 32652370)
21. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H
Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
23. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
[TBL] [Abstract][Full Text] [Related]
24. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
[TBL] [Abstract][Full Text] [Related]
25. Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review.
Atallah-Yunes SA; Kadado AJ; Soe MH
Curr Probl Cancer; 2019 Oct; 43(5):504-510. PubMed ID: 30685067
[TBL] [Abstract][Full Text] [Related]
26. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
27. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L
Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353
[TBL] [Abstract][Full Text] [Related]
30. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
[TBL] [Abstract][Full Text] [Related]
31. Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review.
Mouri A; Kaira K; Shiono A; Miura YU; Kagamu H
In Vivo; 2020; 34(2):877-880. PubMed ID: 32111798
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.
Zhang C; Jiang W; Li G; Li J; Kang Y; Yu X; Ma H; Feng Y
Ann Palliat Med; 2021 Mar; 10(3):3510-3517. PubMed ID: 33849133
[TBL] [Abstract][Full Text] [Related]
33. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
34. Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
Fiorelli A; Perrotta F; Mollica M; Santini M; Vitiello F; Gilli M; Calabrese C; Bianco A
J Cardiothorac Surg; 2019 Mar; 14(1):50. PubMed ID: 30832704
[TBL] [Abstract][Full Text] [Related]
35. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Basnet S; Dhital R; Tharu B
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract][Full Text] [Related]
39. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
[No Abstract] [Full Text] [Related]
40. A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis.
Kartolo A; Towheed T; Mates M
Immunotherapy; 2021 Apr; 13(6):477-481. PubMed ID: 33626928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
